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Abstract: The nuclear factor-κB (NF-κB) plays a central role in the activation and survival 
of lymphocytes. NF-κB, therefore, is pivotal for acquired immunity, but the dysregulation 
of  NF-κB  signaling  leads  to  inflammatory  diseases  and  lymphomagenesis. Accumulating 
evidence has demonstrated that the mucosa-associated lymphoid tissue (MALT) lymphoma-
related molecules, B-cell lymphoma 10 (BCL10) and MALT-lymphoma-translocation gene1 
(MALT1), are essential signaling components for NF-κB and mitogen-activated protein kinase 
(MAPK) activation, mediated by the immunoreceptor tyrosine-based activation motif (ITAM)-
coupled receptors involved in both innate and adaptive immunity. CARMA1 (also referred 
to as CARD11 and Bimp3) is a crucial regulator for ITAM-mediated signaling as it forms a 
complex with BCL10-MALT1 in lymphoid lineage cells such as T, B, natural killer (NK), and 
natural killer T (NKT) cells, known as the lymphoid CARMA1-BCL10-MALT1 (L-CBM) 
complex. In this review, recent understanding of the molecular and biological functions and 
the signal regulation mechanisms of the L-CBM complex are described and its role in disease 
development and potential as a therapeutic target is further discussed.
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Immunoreceptors such as T cell receptors (TCRs), B cell receptors (BCRs), Fc 
receptors (FcRs), activating natural killer cell receptors (NKRs), as well as multiple 
immunoglobulin (Ig)- or C-type lectin-family receptors expressed on myeloid cells, 
transduce activation signals by associating with signaling chains (eg, CD3s, Igα, Igβ, 
FcRγ, and DAP12) containing the immunoreceptor tyrosine-based activation motifs 
(ITAMs), bearing a consensus sequence of YxxL-x6-8-YxxL (where x denotes any 
amino acids), in their cytoplasmic domains.1 Upon engagement of these ITAM-coupled 
receptors, an activation signal cascade is initiated with phosphorylation of specific 
tyrosines in ITAMs by the Src family of kinases.2 The phosphorylated ITAMs recruit 
the tyrosine kinase Syk or zeta-associated protein, 70 kDa (ZAP-70), which bind via 
the tandem Src homology domain 2 (SH2) and initiate a downstream signaling cascade 
leading to activation of transcription factors such as nuclear factor-κB (NF-κB), nuclear 
factor activated T-cells (NFAT), and activating protein-1 (AP-1).
The NF-κB family of transcription factors plays a critical role in immune cell func-
tions such as immune regulation, inflammation, cell survival, and cell cycle progression.3 
Accumulating evidence has revealed that the mucosa-associated lymphoid tissue (MALT) 
lymphoma-related molecules, B-cell lymphoma 10 (BCL10) and MALT-lymphoma-trans-
location gene1 (MALT1), form a complex and play an essential role in NF-κB activation 
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through all of the ITAM-coupled receptors expressed by immune 
cells, as well as some G-protein-coupled   receptors expressed on 
nonimmune cells.4 Recent genetic-based studies have identified 
the two caspase recruitment domain (CARD)-family adaptor 
molecules, CARMA1 (also known as CARD11 and Bimp3) 
and CARD9, regulate the BCL10-MALT1-mediated NF-κB, 
as well as mitogen-activated protein kinase (MAPK) activa-
tion signaling in a cell-type-specific, nonredundant manner. 
CARMA1 acts in lymphoid cells such as T/B lymphocytes 
and natural killer (NK) cells whereas CARD9 acts in myeloid 
cells such as macrophages and dendritic cells (DCs),5–7 and 
thus play a crucial role in both innate and adaptive immune 
responses. Based on their cell specificity, the CARMA1-
BCL10-MALT1 and CARD9-BCL10-MALT1 complexes 
are referred to as the lymphoid CARMA1-BCL10-MALT1 
(L-CBM) complex and the myeloid CARD9-BCL10-MALT1 
(M-CBM) complex, respectively (Figure 1).8 In this article, the 
role of L-CBM-mediated signaling controlled by CARMA1, 
with particular emphasis on its regulation for NF-κB activa-
tion, in lymphocyte development and activation, as well as in 
disease, has been reviewed.
L-CBM signaling in T cells
BCL10 is a member of the CARD family of proteins and associ-
ates with Ig-like domains of MALT1 through its serine/threonine 
(S/T)-rich domain (Figure 1). When overexpressed, this interac-
tion synergistically induces NF-κB activation. CARMA1 is a 
member of CARD-containing   membrane-associated guanylate 
kinase (MAGUK) family and was found to be a binding partner 
of BCL10 via CARD-CARD interaction (Figure 1), similar 
to CARD9 and the other members of the CARD-MAGUKs: 
CARMA2 (CARD14/Bimp2), and CARMA3 (CARD10/
Bimp1).9,10 It is thought that the BCL10-MALT1 complex 
binds to CARMA1 following antigen receptor-triggering to 
form the L-CBM complex. An association of CARMA1 with 
MALT1 and BCL10 via a coiled-coil (C-C) domain was also 
reported, which likely contributes to stabilizing the L-CBM 
complex (Figure 4).11,12 Genetic studies using knockout mice 
of CARMA1, BCL10, and MALT1, as well as a CARMA1-
deficient Jurkat cell line, have demonstrated the physiological 
relevance of the L-CBM complex in TCR and BCR signaling. 
The T cell phenotype of CARMA1-deficent (CARD11−/−) mice 
closely resembles that of BCL10-deficient (BCL10−/−) and 
MALT1-deficient (MALT1−/−) mice.13–16
Peripheral mature T cells from these L-CBM-deficient 
mice show almost complete abrogation of proliferation and 
cytokine production upon TCR stimulation. As a result, these 
mice exhibit impaired T cell immunity.13,15 Loss of L-CBM 
molecules abrogates TCR-induced NF-κB activation owing to 
defective activation of an inhibitor of κB (IκB) kinase (IKK) 
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Figure 1 L-CBM complex and M-CBM complex.
Notes: Structure of CARMA1, CARD9, BCL10 and MALT1 are shown.
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(Figure 2), whereas calcium mobilization and proximal tyrosine 
phosphorylation are unaffected.13,15 In addition, CARMA1 and 
MALT1 deficiency affects the activation of the MAPK c-Jun-N-
terminal kinases (JNK),14,15 particularly JNK2,17 but not the 
other MAPKs, Erk and p38 (Figure 2). The defective JNK2 
activation results in reduced expression of c-Jun. The MAP3K, 
transforming growth factor β kinase 1(TAK1) and the MAPK 
kinase, MKK7, are likely involved in this pathway as upstream 
kinases of JNK2 because these molecules have been shown to 
be associated with BCL10 upon TCR stimulation.17
L-CBM deficiency did not affect overall development 
of thymocytes, with normal percentages and numbers of 
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Figure 2 Schematic signaling pathway mediated by the L-CBM complex in T and B lymphocytes.
Notes: The L-CBM complex acts in the canonical NF-κB (p65/p50, cRel/p50) activation pathway mediated by iKKβ downstream of TCRs and BCRs. L-CBM also controls 
the JNK, particularly JNK2, activation pathway through antigen receptors, leading to c-JUN activation. Upon antigen receptor stimulation, PKCθ in T cells and PKCβ in B 
cells phosphorylate CARMA1 in the PRD region (see Figure 4), enabling the formation and membrane recruitment of the L-CBM complex. iKKβ positively and negatively 
regulates L-CBM signaling. These signaling events are regulated by the recruitment of signaling components to specific membrane domains, such as lipid rafts, after receptor 
triggering. in MZ B cells, L-CBM mediates signals for canonical NF-κB activation through TLR4-Myd88. L-CBM also mediates signals for noncanonical NF-κB (RelB/p52) 
activation mediated by NiK and iKKα downstream of the BAFF receptor (BAFF-R), which regulates the survival of MZ B cells.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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CD4+CD8+, CD4+CD8−, and CD8+CD4− cells, but increased 
CD4−CD8− double negative (DN) cells.13,15 This increase may 
be due to defective thymic egression of a T cell subpopulation 
with a DN phenotype rather than impaired early development 
of conventional T cell precursors, as these DN cells display 
a mature T cell phenotype with high levels of CD3 expres-
sion. No overt developmental changes in conventional CD4 
and CD8 T cells were observed in the peripheral lymphoid 
organs of mice with L-CBM deficiency; however, the number 
of naturally occurring regulatory T cells (nTregs) was mark-
edly reduced in the thymus and periphery.18–20 This phenotype 
could likely be attributed to the defective TCR-mediated 
NF-κB signaling, as T cells deficient for both PKCθ, the 
essential upstream kinase of L-CBM, and IKKβ, which con-
trols canonical NF-κB activation pathway through TCRs, also 
exhibit a similarly significant reduction of nTregs.18 A study 
using CARD11−/− mice revealed that L-CBM controls an early 
checkpoint in Treg development by enabling the generation 
of thymic precursors of Tregs.20 This deficiency is Treg-
intrinsic, and overexpression of a constitutive active STAT5, 
an essential mediator of IL-2/IL-15 receptor signaling, as well 
as of the antiapoptotic protein, BCL2, failed to rescue this 
deficiency, indicating that L-CBM neither controls IL-2/IL-15 
receptor signaling nor mitochondrion-regulated cell survival 
during Treg development. Thus, L-CBM-mediated signaling 
may induce undefined factors essential to commit immature 
thymocytes to the nTreg lineage, although these factors are 
dispensable to conventional T cell development.
L-CBM signaling in B cells
Reduced follicular (FO) and marginal zone (MZ) B cells 
in spleen and an almost complete absence of peritoneal 
B-1 B cells have been consistently observed in CARD11−/−, 
BCL10−/−, and MALT1−/− mice.14,15,21 This deficiency of 
L-CBM molecules results in abrogated BCR-induced NF-κB 
activation and thereby defects in B cell proliferation and 
survival, although one line of MALT1−/− mice has exhibited 
only mild defects in B cell activation through a selective 
defect in c-Rel activation, which controls B cell survival 
(Figure 2).14,22 CARMA1, and probably BCL10, control JNK 
activation through BCRs (Figure 2),15 whereas MALT1 might 
be   dispensable for it.14,16 CD40-induced activation was also 
defective in splenic B cells with L-CBM deficiency,13,16,23 
  possibly owing to defective development of MZ B cells, which 
are the major cells responding to CD40 stimulation.23
The involvement of L-CBM in Toll-like receptor (TLR) 
signaling in B lymphocytes has been suggested, although 
it remains a controversial issue. CARD11−/− whole splenic 
B cells show impaired proliferation upon TLR4 stimula-
tion, probably due to defective JNK activation.15 A similar 
deficiency was observed in one of the MALT1−/− mouse 
models.16 A study that compared FO and MZ splenic B cells 
revealed that BCL10 deficiency affected only MZ B cells in 
response to lipopolysaccharide (LPS) due to impaired NF-κB 
activation (Figure 2).21 The defective LPS response of whole 
splenic B cells from L-CBM deficient mice might be due to 
the reduced number and the impaired response of MZ B cells 
because MZ B cells have been shown to proliferate much 
better than FO B cells upon LPS stimulation.24
NF-κB is activated by either a canonical or a nonca-
nonical pathway.25 The canonical pathway, which depends 
on IKKβ, is activated by engagement of receptors such as 
TNFR1, IL-1R, TLRs, TCR, and BCR. IKKβ phosphory-
lates inhibitors of κB molecules bound to NF-κB subunits 
such as RelA, allowing NF-κB to translocate to the nucleus. 
The noncanonical pathway, which depends on IKKα, is 
activated by engagement of receptors for lymphotoxin β 
(LT-β), RANKL, CD40L, and B-cell activation of the tumor 
necrosis factor (TNF) family (BAFF). IKKα mediates phos-
phorylation-dependent processing of the NF-κB2 precursor, 
p100, resulting in the generation of p52 and its transloca-
tion to the nucleus. As discussed so far, L-CBM signaling 
is crucial for the canonical NF-κB signaling downstream 
of TCRs and BCRs. However, recent reports have shown 
that L-CBM also activates the noncanonical pathway and 
thereby regulates the survival in MZ B cells.26–28 Eµ-driven 
human BCL10-transgenic (Tg) mice exhibit constitutive 
activation of both the canonical and noncanonical NF-κB 
pathway in splenic B cells. The Tg mice show expanded MZ 
and B1 B cells and reduced FO and B1a cells, with some 
older mice developing MZ lymphomas. Lack of MALT1 
impairs BAFF-induced phosphorylation and degradation 
of p100 (Figure 2). The MALT1−/− MZ, but not FO B cells, 
exhibit reduced survival and antiapoptotic gene induction 
in response to BAFF in vitro, likely owing to the elevated 
expression and defective BAFF-induced downregulation of 
TRAF3, a negative modulator of the BAFF-induced survival 
signal, particularly in MZ B cells. The phenotypes of BAFF-
Tg mice, including increased basal serum Ig, MZ B cells, 
and B1 B cells, spontaneous germinal center formation, and 
Ig deposition in the kidney, all disappear in the absence of 
MALT1 and BCL10. In line with these observations, the B 
cell phenotype of L-CBM-deficient mice resembles that of 
the BAFF-R- mutant A/WySnJ mice,29 suggesting a role for 
L-CBM complex in driving the nonclassical NF-κB pathway 
in BAFF-mediated survival of B cells.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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L-CBM signaling in NK cells
NK cells play as a sentinel in protecting against tumors and 
intracellular pathogens. NK cell activation is dependant 
upon multiple germline-encoded activating and inhibitory 
receptors that recognize specific ligands on target cells.30 
These are referred to as activating NK cell receptors 
(NKRs) and inhibitory NKRs, respectively. When activating 
NKR signaling dominates inhibitory NKR signaling, NK 
cells attack targets through two defined effector functions: 
cytotoxicity; and production of proinflammatory cytokines 
and chemokines. The activating NKRs are ITAM-coupled 
receptors and are similar to those in myeloid cells with respect 
to structure and signaling mechanisms; they belong to either 
the Ig or C-type lectin family of receptors and use the same 
ITAM-containing adaptors, DAP12 and FcRγ. The role of 
the L- or M-CBM complex in activating NKR signaling has 
been examined by using CARD9−/−, CARD11−/−, BCL10−/−, 
and MALT1−/− mice.6,7,31 Despite its essential role in myeloid 
DAP12- and FcRγ-associated receptors, CARD9 is not 
required for activation through activating NKRs.6,7 Instead, 
studies have revealed that CARMA1, BCL10, and MALT1 
were essential for production of cytokines and chemokines 
induced by multiple activating NKRs, including FcγRIII 
(CD16), NK1.1, Ly49H, Ly49D, and NKG2D, demonstrat-
ing that L-CBM, not M-CBM, regulates activation of NKR 
signaling (Figure 3). However, these deficiencies do not 
influence either maturation or the repertoire formation of 
peripheral NK cells. Similar to T and B lymphocytes, the loss 
of L-CBM impairs NF-κB activation following activation of 
NKRs (Figure 3). On the other hand, contribution of L-CBM 
to MAPK activation, particularly JNK and p38, is unclear. 
In BCL10−/− and MALT1−/− NK cells, JNK and p38 activation 
is defective upon stimulation with phorbol myristate acetate 
plus calcium ionophore (P/I), which bypasses antigen recep-
tor proximal signaling events by directly activating protein 
kinase Cs (PKCs); while in CARD11−/− NK cells, all MAPK 
activation following CD16 crosslinking is normal (Figure 3). 
Thus, it will be necessary to clarify whether this difference 
reflects different contributions of CARMA1 and BCL10/
MALT1 in NKR-induced MAPK activation or arises from 
alternative signaling activation by different stimuli. Inter-
estingly, the cytotoxicity of NK cells induced by activating 
NKRs is not affected by L-CBM deficiency (Figure 3). This 
corresponds with normal Vav1 phosphorylation and Ca2+ 
mobilization, both of which regulate exocytosis of cytotoxic 
granules, upon activating NKR ligation in CARD11−/− NK 
cells.6 Together, L-CBM controls a distinct function of NK 
cells induced by NKR triggering (ie, cytokine and chemokine 
production, but not cytotoxicity) by selectively regulating the 
NF-κB activation signal.
Signaling regulation of L-CBM 
complex
In this section, we discuss recent advances in the under-
standing of the molecular mechanisms that regulate L-CBM 
signaling. Multiple regulation mechanisms; involving 
phosphorylation, ubiquitylation, oligomerization, caspase 
activation, and recruitment to plasma membrane have been 
proposed to control L-CBM function (Figure 4). Upon activa-
tion of antigen receptors, CARMA1 and BCL10 are phospho-
rylated by several kinases. Phosphorylation by some kinases 
represented by PKCs, positively regulates L-CBM signaling 
by modifying CARMA1 conformation, enabling it to form a 
signalosome with BCL10/MALT1 and downstream compo-
nents for the NF-κB activation pathway.32   Phosphorylation 
by other kinases has been shown to downmodulate L-CBM 
signaling by interfering with signalosome formation or tar-
geting CARMA1 and BCL10 for   degradation.   Cascading 
oligomerization of L-CBM components and downstream 
molecules is a crucial event for the activation of this path-
way. The lysine (K) 63-linked ubiquitination of BCL10 and 
MALT1 following TCR activation provides docking sites 
for downstream signaling molecules such as TRAF6 and 
NEMO, a necessity for the oligomerization cascade lead-
ing to IKK activation. By contrast, it has been reported that 
BCL10 and CARMA1 undergo degradation followed by 
K48-linked ubiquitination after antigen receptor-induced 
activation that may work to limit the amplitude of L-CBM 
signaling. L-CBM complex was shown to interact with cas-
pase-8 and thereby regulate the caspase-8-c-FLIPL-mediated 
NF-κB activation pathway. Paracaspase activity of MALT1 
was recently reported and the proteplytic activity shown to 
fine tune L-CBM-mediated NF-κB signaling. Various lines 
of evidence suggest that plasma membrane recruitment of 
L-CBM molecules is a crucial event for its function in NF-κB 
activation signaling.
Regulation by PKCs
L-CBM deficiency abrogates NF-κB activation in T, B and 
NK cells upon stimulation with P/I,6,7,13–15 indicating that 
L-CBM acts downstream of PKCs. PKC-deficient mice have 
confirmed this notion; the deficiency of PKCθ in T and NK 
cells, and of PKCβ in B cells, resulted in profound defects in 
TCR-, activating NKR- and BCR-induced NF-κB activation, 
respectively.33,34 This regulation could be explained by 
findings that CARMA1 is a direct target of these PKCs. Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Upon antigen receptor stimulation, CARMA1 is phospho-
rylated by PKCθ and PKCβ in the so called PKC-regulated 
domain (PRD),32 which is the linker sequence between the 
C-C and the PDZ domain (Figure 4). At least three serine 
residues (S552, S637, and S645 in human CARMA1) have 
been identified as the target sites.35,36 A model has been 
proposed where PRD phosphorylation destabilizes and 
induces conformational changes of CARMA1 from an 
inhibitory form to an active one that is accessible to BCL10 
and other downstream molecules.11,12,32,37 In contrast to this 
essential PKC-dependent regulation in L-CBM, the fact 
that CARD9 lacks a PRD   suggests that M-CBM-mediated 
signaling cannot be regulated by PKCs in a similar way 
to CARMA1. Indeed, lack of CARD9 or BCL10 in bone 
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Figure 3 Schematic signaling pathway mediated by the L-CBM complex in NK cells.
Notes: The L-CBM complex acts in the canonical NF-κB activation pathway through activating NK cell receptors (NKR) such as Ly49H, Ly49D, NK1.1, NKG2D, FcγRiii, etc. 
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marrow-derived dendritic cells (BMDCs) did not affect IKK 
activation and cytokine production in response to P/I.6 In 
addition, treatment with a PKC inhibitor effectively blocked 
cytokine production through ITAM-coupled receptors in NK 
cells, but not in BMDCs. It was so, even when NK cells and 
BMDCs were activated through the same receptor, CD16. 
This would indicate that PKC activation is required for 
L-CBM-, but not M-CBM-mediated signaling. However, 
loss of CARMA1 abrogates P/I-induced NF-κB activation 
in BMDCs, suggesting that CARMA1 is essential for PKC-
mediated NF-κB activation in both lymphoid and myeloid 
cells, although the PKC-CARMA1 axis in myeloid cells is 
not utilized downstream of myeloid ITAM receptors, but 
might be used in signaling through other receptors. In line 
with this, the overexpression of CARD9 in CARMA1-defi-
cient cells failed to restore PKC-mediated NF-κB activation. 
Therefore, these results indicate that L-CBM and M-CBM 
signaling are regulated by different molecular mechanisms 
and thus they are functionally not interchangeable.
Regulation by other kinases
It has been suggested that L-CBM signaling is regulated 
through phosphorylation by kinases other than PKCs. 
Calmodulin-dependent protein kinase (CaMKII) phos-
phorylates CARMA1 on Ser109 after TCR engagement 
and facilitates the interaction between CARMA1 and 
BCL10 (Figure 4).38 CaMKII also phosphorylates BCL10 
on Ser138 but this phosphorylation is involved in the 
attenuation of NF-κB activation (Figure 4).39 Hematopoi-
etic progenitor kinase 1 (HPK1) has been suggested to be 
involved in the JNK and NF-κB pathways in TCR signaling 
and regulates activation and survival of T cells.40 A recent 
report has shown that HPK1 interacts with CARMA1 after 
TCR stimulation and phosphorylates CARMA1 on Ser549 
and Ser551 within the PRD (Figure 4). Although the precise 
mechanism is unclear, this phosphorylation is critical for 
TCR-mediated NF-κB activation and IL-2 production in 
Jurkat cells.40 IKKβ phosphorylates CARMA1 on Ser578 
and probably on Thr119 in chickens (corresponding to 
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Ser555 and Thr110 in humans, respectively) upon BCR 
stimulation (Figure 4).41 This phosphorylation is postulated 
to enhance the assembly of the L-CBM complex, resulting 
in an increased ability of CARMA1 to activate IKK. Other 
studies have suggested that IKKβ phosphorylates BCL10 
on five serines within the MALT1-interacting, S/T-rich 
domain and on Thr81 and Ser55 within CARD, upon TCR 
stimulation (Figure 4).42,43 The former causes disengage-
ment of BCL10 from MALT1 and interferes with IKK 
ubiquitination and the latter induces BCL10 degradation via 
the β-TrCP ubiquitin ligase/  proteasome pathway, resulting 
in negative regulation and attenuation of L-CBM-mediated 
NF-κB signaling. Casein kinase (CK) 1α has a contrast-
ing role in L-CBM signaling. CK1α associates with the 
L-CBM complex through the PRD of CARMA1 after TCR 
stimulation and participates in NF-κB activation, prolif-
eration, and cytokine production. However, CK1α kinase 
activity subsequently contributes to the negative feedback 
of NF-κB activation by phosphorylating CARMA1 on 
Ser608 (Figure 4).44
Regulation by oligomerization  
and ubiquitination
Oligomerization and its associated ubiquitination events play 
an important role in L-CBM signaling. A recent study indicated 
that CARMA1 constitutively oligomerizes via its C-C domain 
and this self-oligomerization is required for TCR-induced 
NF-κB activation (Figure 4).45 Similarly, a previous study 
using mice bearing a point mutation (Leu298Gln) in the C-C 
domain of CARMA1, which is likely to disrupt C-C domain 
structure, demonstrated that integrity of the C-C domain is 
crucial for antigen receptor-induced IKK and JNK activation 
(Figure 4).46 CARMA1 forms an active conformation after 
receptor stimulation, which is followed by the recruitment of 
downstream molecules, triggering a downstream oligomeriza-
tion and ubiquitination cascade.32,47 BCL10-dependent MALT1 
oligomerization induces activation of TNF receptor-associated 
factor (TRAF) 6, a ubiquitin ligase, which in turn activates 
the IKK complex through lysine (K) 63-linked ubiquitylation 
of the regulatory subunit of IKK NEMO (an essential NF-κB 
modulator). During this process, TRAF6 itself is self-ubiq-
uitinated, enabling recruitment of TAK1 and TAK1-binding 
protein 2 (TAB2), which then activates IKKα and IKKβ by 
phosphorylation.48 BCL10 and MALT1 also undergo K63-
linked ubiquitination in the CARD domain and the C-terminal 
region, respectively, upon T cell activation, which is likely 
to provide a docking surface for the recruitment of NEMO 
(Figure 4).49,50 Interestingly, Zhou et al reported that MALT1 
itself has an E3-ligase activity at C-terminus that targets both 
MALT and NEMO for ubiquitination.51
In contrast, signaling inhibition by ubiquitination of 
L-CBM components has also been reported. CARMA1 is 
K48-linked-polyubiqutinated in the MAGUK region and 
degraded by the proteasome after antigen receptor-induced 
activation in T and B cells (Figure 4).52 The ubiquitination-
dependent degradation of CARMA1 requires the phospho-
rylation of the PRD by PKC. A region between SH3 and the 
guanylate kinase domain (GUK), termed the Hook domain, 
plays a regulatory role in this process. Elimination of the ubiq-
uitination sites from the MAGUK region results in elevated 
basal and inducible NF-κB and JNK activation, thus this 
activation-dependent mechanism likely provides an intrinsic 
feedback control of L-CBM signaling. In vitro experiments 
have suggested that the cellular inhibitor of apoptosis protein 
(cIAP) might target this MAGUK ubiquitination, although a 
cIAP antagonist that depletes the endogenous pool of cIAP 
did not affect P/I-induced CARMA1 degradation. Another 
ubiquitination-mediated negative regulation of CARMA1 has 
been suggested where Cbl-b-promoted monoubiquitination of 
CARMA1 is involved in the anergy induction in NKT cells.53 It 
has been shown that BCL10 undergoes degradation following 
ubiquitination after activation of lymphocytes through antigen 
receptors,43,54,55 resulting in termination of L-CBM signaling 
(Figure 4). NEDD, cIAP, β-TrCP, and Itch have been suggested 
as ubiquitin ligases (E3) of BCL10. Both the proteasomal 
pathway via β-TrCP and the lysosomal pathway via NEDD 
and Itch have been proposed for BCL10 degradation.43,54,55 The 
proteasomal pathway requires the phosphorylation of CARD by 
IKKβ,43,54,55 while the lysosomal pathway requires intact CARD 
and the novel PKC activity.43,54,55 The COP9 signalosome 
(CNS), a pleiotropic regulator of the ubiquitin/26S proteasome 
system, controls antigen responses in T cells. The CNS subunit 
5 (CNS5) has been shown to interact with L-CBM in activated 
T cells. The CNS5, as well as CNS2, fine tunes IKK activation 
by maintaining BCL10 stability, most likely by interfering with 
the polyubiquitination and degradation of BCL10 (Figure 4).56 
The deubiquitinating enzyme, A20, has been shown to func-
tion as a negative regulator for T cell activation.57 Duwel et al 
have recently reported that A20 catalyzes the removal of the 
K63-linked ubiquitin chains attached to MALT1 and therefore 
regulates duration and strength of IKK activity (Figure 4).58
Regulation by caspases
MALT1 was originally identified as a caspase homolog 
named paracaspase.59 Recent studies have revealed that 
the paracaspase domain of MALT1 possesses protease Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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activity, cleaving BCL10,60 and the NF-κB inhibitor, A2061 
(Figure 4). Although the protease activity is required for 
optimal activation of NF-κB following TCR ligation, the 
MALT1-dependent BCL10 cleavage is not required for 
activation of NF-κB and JNK. Instead, it is necessary for 
TCR-induced cell adhesion to the extracellular matrix protein 
fibronectin. In contrast to other cells, lymphoid cells, par-
ticularly T cells, constitutively express A20. The cleavage of 
A20 by MALT1 disrupts its inhibitory effect on TCR-induced 
NF-κB activation and IL-2 production. The proteolytic activ-
ity of MALT1, therefore, is likely to act as a fine tuner in 
L-CBM signaling. This activity of MALT1 might not to be 
involved in M-CBM signaling because BCL10 cleavage was 
not detected when THP-1 monocytic cells were stimulated 
through ITAM-coupled receptors.60
Besides its established role in lymphocyte apoptosis, 
  caspase-8 and its proteolytically inactive homolog, c-FLIPL, 
are known to be essential for lymphocyte activation in both 
mice and humans,62–64 probably by interacting with the 
L-CBM complex and regulating NF-κB activation. A study 
has shown that MALT1 directly associates with   procaspase-8 
and induces limited autoprocessing of procaspase-8 
(Figure 4),65 which generates an active form of caspase-8 that 
lacks the capacity to activate apoptotic substrates including 
caspase-3, but retains activity toward c-FLIPL to generate 
p43-FLIP. The cleaved form of c-FLIPL can strongly induce 
activation of NF-κB signaling pathway through interaction 
with TRAF2.66 The association of caspase-8 with CARD and 
the C-C domain of the ‘active’ form of CARMA1 has also 
been reported (Figure 4).12
Regulation by membrane recruitment
Membrane recruitment is a crucial event in L-CBM-mediated 
NF-κB activation. It has been reported that BCL10, PKCθ, 
PKCβ, MALT1, procaspase-8, c-FLIPL, and the IKK complex 
are recruited into lipid rafts after antigen receptor stimulation 
and that this recruitment is crucial for NF-κB activation.33,67,68 
CARMA1 resides in both the cytoplasm and lipid rafts of rest-
ing cells, but the amount of CARMA1 in lipid rafts increases 
after activation. This localization of CARMA1 is of particular 
importance for L-CBM signaling because mutations such 
as Leu808Pro mutation (L808P in Figure 4) that disrupt 
membrane localization of CARMA1 impair TCR-induced 
NF-κB activation.45,67 Genetic studies have demonstrated that 
CARMA1 is essential for the recruitment of BCL10-MALT1 
and IKK complexes to lipid rafts.67,69
CARMA1 was also shown to control PKCθ recruitment 
in Jurkat cells.67 An SLP-76-binding molecule, adhesion and 
degranulation-promoting adapter protein (ADAP), which 
functions in the inside-out signaling for integrin activation, 
has been shown to be critical for TCR-mediated NF-κB acti-
vation by acting as a link between the   TCR-ZAP70-SLP76 
signaling complex and L-CBM by binding to CARMA1 
(Figure 4). ADAP-deficient T cells revealed impaired L-CBM 
complex formation in the membrane and defective NF-κB 
activation.70 It has been shown that 3-phosphoinositide-
dependent kinase 1 (PDK1) recruits PKCθ and CARMA1 
to lipid rafts upon TCR stimulation (Figure 4).71 A recent 
study using mice with a T cell-specific deletion of PKD1 
has revealed that CD28 ligation facilitates NF-κB activation 
by regulating immune synapse localization and phospho-
rylation of PDK1, which enables the binding of PKCθ and 
CARMA1.72 In contrast to the essential role of PDK1 in 
TCR-mediated NF-κB   activation, the deletion of PDK1 in 
a chicken B cell line does not alter BCR-mediated NF-κB 
activation,41 indicating a possible difference in the regula-
tion mechanism of L-CBM recruitment to the membrane in 
TCR- versus BCR-mediated signaling pathways for NF-κB 
activation.
L-CBM signaling in disease
Three chromosomal translocations of L-CBM genes, t(11;18)
(q21;q21), t(1;14)(p22;q32), and t(14;18)(q32;q21), have 
been reported and well characterized in MALT lymphoma 
(MALTL).73 The MALT1 gene was originally identified 
in a break point of t(11;18)(q21;q21). This translocation 
generates API2-MALT1 fusion products that comprise the 
N-terminus of API2 with three intact baculovirus IAP repeat 
(BIR) domains and the C-terminus of the MALT1 with intact 
caspase-like domains. The fusion product, but neither API2 
nor MALT1 alone, is capable of activating NF-κB. The trans-
locations, t(1;14)(p22;q32) and t(14;18)(q32;q21), bring the 
BCL10 and MALT1 genes under the regulatory control of the 
Ig heavy chain (IgH) enhancer, respectively, thereby deregu-
lating its expression and culminating in aberrant NF-κB 
activation. In addition to chromosomal translocations, 
BCL10 gene amplification has been reported in pancreatic 
cancer and nodal diffuse large B cell lymphoma (DLBCL).74 
Similarly, MALT1 gene amplification was found in cell lines 
of marginal zone B cell lymphoma and DLBCL.75,76
In contrast to normal B cells that express BCL10 in 
the cytoplasm, MALT lymphoma cells bearing t(11;18)
(q21;q21) and t(1;14)(p22;q32) express the protein predomi-
nantly in the nucleus. Shen et al reported that 70% (28/40) 
of nasal NK/T cell lymphoma (NL) cases demonstrated 
aberrant nuclear staining of BCL10 and concomitant nuclear Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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localization of NF-κB, although t(11;18)(q21;q21) and 
t(1;14)(p22;q32) are not present in NLs, indicating a possible 
relationship between aberrant BCL10 nuclear localization 
and tumorigenesis.77
Among the subtypes of DLBCL, the least curable 
activated-B-cell-like (ABC) subtype DLBCLs, but not the 
germinal center B cell-like (GCB) subtype, relies on con-
stitutive NF-κB signaling for survival. A loss-of-function 
RNA interference screen for genes required for survival of 
ABC DLBCL revealed that CARMA1 is a key upstream 
signaling component responsible for the constitutive IKK 
activity in ABC DLBCL.78 In line with this, oncogenic mis-
sense mutations of the CARMA1 gene, all within exons 
encoding the C-C, have been found in ABC DLBCL.79 These 
mutations constitutively activate the NF-κB pathway and 
enhance   antigen receptor signaling to NF-κB, possibly owing 
to aggregate formation of the mutant proteins. MALT1 is 
constitutively active in ABC DLBCL, but not GCB DLBCL 
lines.80 The oncogenic forms of CARMA1 are more potent 
than wild type CARMA1 in inducing proteolytic activity of 
MALT1. Inhibition of MALT1 activity, with the inhibitor 
z-VRPR-fmk, specifically affected the growth and survival of 
ABC DLBCLs. Thus, the MALT1 proteolytic activity might 
be a promising target for DLBCL therapy.
BCL10-transgenic mice elevate BAFF expression and 
specifically promote survival of MZ B cells and some mice 
develop splenic MZ lymphomas (MZL).26 It has been reported 
that BAFF overexpression, with concomitant nuclear expres-
sion of BCL10 and NF-κB activation, is associated with 
Helicobacter pylori-independent growth of gastric DLBCL 
with histologic evidence of MALT lymphoma.81 Thus, 
L-CBM-regulated BAFF signaling and vice versa might con-
tribute to the development of MALTL, MZL, and DLBCL.
L-CBM, therefore, is an attractive therapeutic target 
for B-cell lymphomas and diseases associated with aber-
rant lymphocyte activation. However, further elucidation of 
L-CBM signaling is required for such applications, especially 
in approaches utilizing suppression of L-CBM activity. Mice 
with the Leu298Gln (L298Q in Figure 4) point mutation 
in CARMA1 exhibit profound defects in humoral immune 
response, whereas, paradoxically, the mice develop a hyper-
IgE syndrome with atopic manifestations as they age.46 This 
indicates that the amplitude of L-CBM signaling balances 
immunity versus tolerance and is thereby involved in the 
maintenance of immune homeostasis.
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